A citation-based method for searching scientific literature

Marcela G del Carmen, Michael Birrer, John O Schorge. Gynecol Oncol 2012
Times Cited: 146







List of co-cited articles
498 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Michael S Anglesio, Mark S Carey, Martin Köbel, Helen Mackay, David G Huntsman. Gynecol Oncol 2011
171
30

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
John K Chan, Deanna Teoh, Jessica M Hu, Jacob Y Shin, Kathryn Osann, Daniel S Kapp. Gynecol Oncol 2008
266
29


ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
23

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Aikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki,[...]. Int J Gynecol Cancer 2014
76
28

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
823
20

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
William E Winter, G Larry Maxwell, Chunqiao Tian, Jay W Carlson, Robert F Ozols, Peter G Rose, Maurie Markman, Deborah K Armstrong, Franco Muggia, William P McGuire. J Clin Oncol 2007
571
16

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato,[...]. J Clin Oncol 2016
73
21

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Hiroaki Itamochi, Junzo Kigawa, Naoki Terakawa. Cancer Sci 2008
171
15

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
M Takano, Y Kikuchi, N Yaegashi, K Kuzuya, M Ueki, H Tsuda, M Suzuki, J Kigawa, S Takeuchi, H Tsuda,[...]. Br J Cancer 2006
187
15

Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.
Paul J Hoskins, Nhu Le, Blake Gilks, Anna Tinker, Jennifer Santos, Frances Wong, Kenneth D Swenerton. J Clin Oncol 2012
72
20

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Seiji Mabuchi, Toru Sugiyama, Tadashi Kimura. J Gynecol Oncol 2016
62
22

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
165
13

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuan-Ting Kuo, Tsui-Lien Mao, Siân Jones, Emanuela Veras, Ayse Ayhan, Tian-Li Wang, Ruth Glas, Dennis Slamon, Victor E Velculescu, Robert J Kuman,[...]. Am J Pathol 2009
297
13

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
B A Goff, R Sainz de la Cuesta, H G Muntz, D Fleischhacker, M Ek, L W Rice, N Nikrui, H K Tamimi, J M Cain, B E Greer,[...]. Gynecol Oncol 1996
273
12

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
537
11


Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
K Yamaguchi, M Mandai, T Oura, N Matsumura, J Hamanishi, T Baba, S Matsui, S K Murphy, I Konishi. Oncogene 2010
119
10


IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Michael S Anglesio, Joshy George, Hagen Kulbe, Michael Friedlander, Danny Rischin, Charlotte Lemech, Jeremy Power, Jermaine Coward, Prue A Cowin, Colin M House,[...]. Clin Cancer Res 2011
162
9

Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.
Yoo-Young Lee, Tae-Joong Kim, Min-Ji Kim, Ha-Jeong Kim, Taejong Song, Min Kyu Kim, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim. Gynecol Oncol 2011
56
16

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Akira Tsuchiya, Michiie Sakamoto, Jun Yasuda, Makoto Chuma, Tsutomu Ohta, Misao Ohki, Toshiharu Yasugi, Yuji Taketani, Setsuo Hirohashi. Am J Pathol 2003
225
9

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
627
9

Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Catherine A Shu, Qin Zhou, Anjali R Jotwani, Alexia Iasonos, Mario M Leitao, Jason A Konner, Carol A Aghajanian. Gynecol Oncol 2015
40
22

Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Seiji Mabuchi, Chiaki Kawase, Deborah A Altomare, Kenichirou Morishige, Masami Hayashi, Kenjiro Sawada, Kimihiko Ito, Yoshito Terai, Yukihiro Nishio, Andres J Klein-Szanto,[...]. Mol Cancer Ther 2010
54
16

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Michael L Friedlander, Kenneth Russell, Sherri Millis, Zoran Gatalica, Ryan Bender, Andreas Voss. Int J Gynecol Cancer 2016
45
20

Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Masashi Takano, Hiroshi Tsuda, Toru Sugiyama. J Exp Clin Cancer Res 2012
52
17


The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
Liat Hogen, Gillian Thomas, Marcus Bernardini, Dina Bassiouny, Harinder Brar, Lilian T Gien, Barry Rosen, Lisa Le, Danielle Vicus. Gynecol Oncol 2016
16
56

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
David R Crotzer, Charlotte C Sun, Robert L Coleman, Judith K Wolf, Charles F Levenback, David M Gershenson. Gynecol Oncol 2007
101
9

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Helen J Mackay, Mark F Brady, Amit M Oza, Alexander Reuss, Eric Pujade-Lauraine, Ann M Swart, Nadeem Siddiqui, Nicoletta Colombo, Michael A Bookman, Jacobus Pfisterer,[...]. Int J Gynecol Cancer 2010
182
8

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
27
29

Ovarian clear cell adenocarcinoma: a continuing enigma.
David S P Tan, Stan Kaye. J Clin Pathol 2007
83
8

Ovarian cancer.
Gordon C Jayson, Elise C Kohn, Henry C Kitchener, Jonathan A Ledermann. Lancet 2014
996
7

Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
J P Orezzoli, A H Russell, E Oliva, M G Del Carmen, J Eichhorn, A F Fuller. Gynecol Oncol 2008
70
10

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Martin Köbel, Steve E Kalloger, Niki Boyd, Steven McKinney, Erika Mehl, Chana Palmer, Samuel Leung, Nathan J Bowen, Diana N Ionescu, Ashish Rajput,[...]. PLoS Med 2008
562
7

Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.
Shinya Matsuzaki, Kiyoshi Yoshino, Yutaka Ueda, Satoko Matsuzaki, Mamoru Kakuda, Akiko Okazawa, Tomomi Egawa-Takata, Eiji Kobayashi, Tadashi Kimura. Cancer Cell Int 2015
23
30


Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.
Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Eiko Yamamoto, Sawako Fujiwara, Tomokazu Umezu, Shiro Suzuki, Toru Nakanishi, Tetsuro Nagasaka, Fumitaka Kikkawa. Int J Gynecol Cancer 2012
26
26


Rethinking ovarian cancer: recommendations for improving outcomes.
Sebastian Vaughan, Jermaine I Coward, Robert C Bast, Andy Berchuck, Jonathan S Berek, James D Brenton, George Coukos, Christopher C Crum, Ronny Drapkin, Dariush Etemadmoghadam,[...]. Nat Rev Cancer 2011
824
6

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Seiji Mabuchi, Chiaki Kawase, Deborah A Altomare, Kenichirou Morishige, Kenjiro Sawada, Masami Hayashi, Masahiko Tsujimoto, Mareo Yamoto, Andres J Klein-Szanto, Russell J Schilder,[...]. Clin Cancer Res 2009
117
6

Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study.
Giovanna Scarfone, Alice Bergamini, Stefania Noli, Antonella Villa, Sonia Cipriani, Gianluca Taccagni, Paola Vigano', Massimo Candiani, Fabio Parazzini, Giorgia Mangili. Gynecol Oncol 2014
48
12

Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Martin Köbel, Steve E Kalloger, David G Huntsman, Jennifer L Santos, Kenneth D Swenerton, Jeffrey D Seidman, C Blake Gilks. Int J Gynecol Pathol 2010
227
6

Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.
Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni. PLoS One 2013
56
10

Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection.
Toyomi Satoh, Masayuki Hatae, Yoh Watanabe, Nobuo Yaegashi, Osamu Ishiko, Shoji Kodama, Satoshi Yamaguchi, Kazunori Ochiai, Masashi Takano, Harushige Yokota,[...]. J Clin Oncol 2010
112
6


Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
Takako Okamoto, Masaki Mandai, Noriomi Matsumura, Ken Yamaguchi, Hiroshi Kondoh, Yasuaki Amano, Tsukasa Baba, Junzo Hamanishi, Kaoru Abiko, Kenzo Kosaka,[...]. Mol Carcinog 2015
41
14


Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.